ABS Direct Equity Fund’s Praxis Precision Medicines PRAX Stock Holding History

ABS Direct Equity Fund’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-400	Closed	-$135K	–	140
2026 Q1	$135K	Buy	+400	New	+$124K	0.1%	99

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ABS Direct Equity Fund's PRAX Position: Q2 2026 in Review

ABS Direct Equity Fund sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 400 shares — an estimated $135K sold.

ABS Direct Equity Fund first reported a position in PRAX in Q1 2026 and held it in 1 quarter. The position peaked at $135K in Q1 2026. 311 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

ABS Direct Equity Fund reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
ABS Direct Equity Fund sold 400 Praxis Precision Medicines shares in Q2 2026, an estimated $135K.
ABS Direct Equity Fund first reported a position in Praxis Precision Medicines in Q1 2026 and held it in 1 quarter.
ABS Direct Equity Fund's Praxis Precision Medicines position peaked at $135K in Q1 2026.
311 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.